We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.60 | -3.87% | 39.70 | 39.40 | 40.00 | 41.30 | 39.55 | 41.30 | 378,350 | 16:35:07 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 3.1M | -6.51M | -0.0217 | -18.43 | 120.28M |
From May 2019 to May 2024
TIDMFUM
RNS Number : 2556J
Futura Medical PLC
03 December 2018
Futura Medical plc
("Futura" or "the Company")
Total Voting Rights
3 December 2018
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology announces that, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 204,583,439 Ordinary Shares.
Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 204,583,439 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Hot Features
Premium
For further information please For media enquiries please contact:
contact:
Futura Medical plc Optimum Strategic Communications
Angela Hildreth, FD/COO Mary Clark/ Hollie Vile/ Ellie
Blackwell
investor.relations@futuramedical.com Email: futuramedical@optimumcomms.com
www.futuramedical.com Tel: +44 (0) 203 950 9144
Tel: +44 (0) 1483 685 670
Nominated Advisor/Broker
N+1 Singer
Aubrey Powell/ Ben Farrow (Corporate
Finance)
Tom Salvesen/ Mia Gardner (Corporate
Broking)
Tel: +44 (0) 20 7496 3000
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
TVRKMMGZZFNGRZM
(END) Dow Jones Newswires
December 03, 2018 08:00 ET (13:00 GMT)
1 Year Futura Medical Chart |
1 Month Futura Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
